Nama's AI scorecard currently rates Ultragenyx Pharmaceutical Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does RARE report earnings?

Ultragenyx Pharmaceutical's next scheduled report is on Feb 9, 2027. Analysts expect EPS of -$0.66.

What is the RARE price target?

The median analyst price target from 20 analysts is $24.00, with a range of $16.00 – $39.00.

Is RARE Shariah compliant?

Nama's AAOIFI-style screen reads Ultragenyx Pharmaceutical as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Ultragenyx Pharmaceutical (RARE)

Healthcare · Biotechnology · NASDAQ

Ultragenyx Pharmaceutical (RARE) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.57B and a free-cash-flow yield of -32.0%. Over the most recent reported fiscal year, revenue grew 20.2%. Nama's AI scorecard rates it Sell, 3.0 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Sell · 3.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Trailing · -51.9% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-82.5%

How far the last close sits under the highest price of the past five years.

Market cap	$1.57B
Trailing P/E	—
Price / book	—
Price / sales	2.1
FCF yield	-32.0%
Dividend yield	—
Gross margin	83.1%
Operating margin	-73.6%
Net margin	-81.7%
Revenue growth (YoY)	+20.2%
Revenue growth (3-yr annual)	+22.8%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

RARE earnings

Next report: Feb 9, 2027 (Q4 2026, EPS estimate -$0.66). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	-$1.16	-$0.75	-54.7%	$173.00M
Q2 2026	Aug 4, 2026	-$0.90	-$1.00	+10.0%	$214.00M
Q1 2026	May 5, 2026	-$1.54	-$1.46	-5.5%	$136.00M
Q4 2025	Feb 12, 2026	-$1.29	-$1.17	-10.3%	$207.28M

RARE analyst price target

Median target $24.00 from 20 analysts, ranging $16.00 – $39.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live RARE data on Nama Insights →

Recent Congressional trades

Ultragenyx Pharmaceutical trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Oct 12, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Mar 9, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Sep 12, 2025
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Aug 14, 2025

RARE FAQ

Is RARE a buy?: Nama's AI scorecard currently rates Ultragenyx Pharmaceutical Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does RARE report earnings?: Ultragenyx Pharmaceutical's next scheduled report is on Feb 9, 2027. Analysts expect EPS of -$0.66.
What is the RARE price target?: The median analyst price target from 20 analysts is $24.00, with a range of $16.00 – $39.00.
Is RARE Shariah compliant?: Nama's AAOIFI-style screen reads Ultragenyx Pharmaceutical as Not Shariah Compliant. At least one of the three ratios or the industry test failed.